Blaze Bioscience Stock
Blaze Bioscience develops and commercializes products that assist surgeons to treat cancer patients.
Sign up today and learn more about Blaze Bioscience Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Blaze Bioscience Stock
Funding History
| June 2012 | $6.4M |
|---|---|
| June 2015 | $9.7M |
| April 2016 | $0 |
| October 2017 | $16.1M |
| May 2018 | $3.0M |
Management
Founder
James Olson
President & CEO
Heather Franklin
Senior Director of Process Development & Manufacturing
Claudia Jochheim
Vice President, Research & Project Management
Julia Novak
Vice President, Finance & Operations
Mila Lobanova
Press
sec - Apr, 14 2020
FORM Dgeekwire - Apr, 9 2020
Blaze Bioscience gets Fast Track approval from FDA for ‘Tumor Paint’ that helps remove brain tumorsxconomy - Feb, 21 2019
Blaze Bio Raises $5M to Help Surgeons See Tumors From Healthy Tissuexconomy - Jun, 21 2018
What’s Hot in Seattle Biotech: Tech, Life Sciences Convergence & Moreseattletimes - Mar, 14 2018
Surgeons test glowing dyes to find hidden cancer cellsxconomy - Mar, 6 2017
Join Xconomy in June for ‘What’s Hot In Cancer Immunotherapy 2017’businesswire - May, 31 2016
Blaze Bioscience Announces Trial in Progress Presentation at ASCO 2016 Annual Meetingxconomy - Mar, 31 2016
Seattle Week in Review: The March Madness of an Impressionable Teen AIbusinesswire - Sep, 29 2015
Blaze Bioscience Appoints Jan Öhrström, M.D., to Its Board of Directorsbusinesswire - Sep, 29 2015
Blaze Bioscience Announces Poster Presentation at the American Academy of Dermatology 73rd Annual Meetingbusinesswire - Sep, 29 2015
Blaze Bioscience Announces Poster Presentation at the American Academy of Dermatology 73businesswire - Sep, 29 2015
Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Patients with Solid Tumor Cancersbusinesswire - Sep, 29 2015
Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Patients with Solid Tumor Cancersbusinesswire - Sep, 29 2015
Blaze Bioscience’s BLZ-100 Receives Orphan Drug Designation from FDA for Brain Cancerbusinesswire - Sep, 29 2015
Blaze Bioscience’s BLZ-100 Receives Orphan Drug Designation from FDA for Brain Cancerprweb - Sep, 29 2015
Gateway for Cancer Research℠ Funds “Tumor Paint” Clinical Trial; Open Enrollment Begins for Children with Brain Cancer at Seattle Children’s Hospitalbusinesswire - Sep, 29 2015
Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Children with Brain Cancerbusinesswire - Sep, 29 2015
Blaze Bioscience Announces Poster Presentation at ASCO 2015 Annual Meetingwired - Sep, 29 2015
One Doctor’s Quest to Save People by Injecting Them With Scorpion Venomgeekwire - Sep, 29 2015
GeekWire Awards: Vote for Geek of the Yeargeekwire - Sep, 29 2015
Deals of the Year: The top 28 venture capital investments we tracked in 2013geekwire - Sep, 29 2015
Tumor paint startup Blaze Bioscience raises $9M to help surgeons pinpoint cancer cellsgeekwire - Sep, 29 2015
Geek of the Week: Dr. Jim Olson’s ‘Project Violet’ is crowdfunding potential cures for cancergeekwire - Sep, 29 2015
Welcome to the Northwest (where startups are cheaper than the Valley)geekwire - Sep, 29 2015
Blaze Bioscience raises $8.5M to help surgeons pinpoint cancer cells with ‘tumor paint’geekwire - Sep, 29 2015
Seattle angel group Keiretsu Forum invests $20M in 34 startups in 2012geekwire - Sep, 29 2015
Keiretsu Forum invests $15.8 millionxconomy - May, 22 2015
Blaze Bioscience Snags $9M More to Take "Tumor Paint" to the Clinic | Xconomyxconomy - May, 22 2015
Blaze Bioscience, Fred Hutch Spinoff with Zymo Vet at the Helm, Seeks to "Paint" Tumors | Xconomyxconomy - May, 22 2015
See You This Afternoon at 'Reinventing Biotech's Business Model' | Xconomyxconomy - May, 22 2015
Fred Hutch Spinoff Blaze Bioscience Pulls in $5M For 'Tumor Paint' | Xconomyxconomy - May, 22 2015
Blaze Bioscience Caps Off $8.5M Financing, Charges Toward Clinic | Xconomyxconomy - May, 22 2015
Amgen Cuts 70 Washington Jobs, Hutch Spins Off Blaze Bioscience, Henney Enters the Hall, & More Seattle-Area Life Sciences News | Xconomyventurebeat - May, 20 2015
Venture capital activity 'sluggish' and continuing to decline in Q1 2013 | VentureBeat | Deals | by Rebecca Grantventurebeat - May, 20 2015
26 amazing startups you need to watch in 2014 | VentureBeat | Business | by Dylan Tweneyxconomy - Apr, 15 2015
Join Us May 6 at the Hutch to Discuss Seattle Biotech's Wild Ride | XconomyEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
